Liraglutide Preserves Insulin-Producing Cell Function and Extends Remission in Newly Diagnosed Type 1 Diabetes

This was a multicenter, double-blind, parallel-group, randomized controlled trial. Sixty-eight adults newly diagnosed with type 1 diabetes who still had measurable insulin production (stimulated C-peptide > 0.2 nmol/L) were randomly assigned 1:1 to receive either 1.8 mg liraglutide or placebo daily for 52 weeks, followed by 6 weeks of observation on insulin alone. Beta cell function was assessed using C-peptide area under the curve from a 4-hour liquid mixed-meal test.

Type 1 diabetes is an autoimmune disease that destroys insulin-producing beta cells. There is currently no approved treatment to slow this destruction. This trial shows that a widely available GLP-1 drug can temporarily preserve remaining beta cell function in the critical first year after diagnosis — a 'honeymoon period' when intervention may have the most impact. While the effect didn't last after stopping the drug, it opens the door to combination strategies that might achieve lasting remission.

GLP-1 receptor agonists are primarily approved for type 2 diabetes and obesity, but researchers are increasingly exploring whether they can help in type 1 diabetes too. This trial — called NewLira — provides some of the strongest evidence yet that liraglutide can extend the honeymoon phase in newly diagnosed type 1 diabetes. The fact that the effect disappeared after stopping treatment suggests any future strategy would need to be ongoing or combined with immune-modulating therapies.

The sample size of 68 patients was relatively small for detecting durable clinical effects. The protective effect on beta cells did not persist after liraglutide was stopped, raising questions about whether continuous treatment would be practical. The study only followed patients for 58 weeks total, so long-term outcomes remain unknown. Gastrointestinal side effects, though transient, were common with liraglutide.